{"created":"2023-05-18T10:11:24.224825+00:00","id":3141,"links":{},"metadata":{"_buckets":{"deposit":"6e37246c-7e68-4baa-bfb1-d34ff21d4360"},"_deposit":{"created_by":1,"id":"3141","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"3141"},"status":"published"},"_oai":{"id":"oai:yamanashi.repo.nii.ac.jp:00003141","sets":["205:251:293"]},"author_link":["14639","14637","14635","14636","14640","14638"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1992","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"95","bibliographicPageStart":"89","bibliographicVolumeNumber":"7","bibliographic_titles":[{"bibliographic_title":"山梨医科大学雑誌"},{"bibliographic_title":"山梨医科大学雑誌","bibliographic_titleLang":"en"}]}]},"item_10001_creator_2":{"attribute_name":"著者名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NAKAGOMI, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"IWASAKI, Masaru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TAKANO, Kunio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MATSUKAWA, Tetsunosuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"UENO, Akira"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"UMEKITA, Nobutaka"}],"nameIdentifiers":[{}]}]},"item_10001_description_5":{"attribute_name":"内容","attribute_value_mlt":[{"subitem_description":"Since 1986, we have been investigating repetitive intraportal administration of anticancer agents as prophylaxis for liver metastasis after gastrointestinal cancer surgery. Intraportal mitomycin C (MMC: 4 mg) was given on the day of operation and on postoperative days 1-6. A preliminary pharmacokinetic study of intraportal MMC administration was performed in a rabbit model. A high first-pass extraction ratio was found at doses of 0.05 and 0.1 mg/kg, and it decreased at the higher doses of 0.2 and 0.4 mg/kg. The clinical dose of 4 mg corresponded to 0.05-0.1 mg/kg in the rabbit model and was considered to be within the optimal dose range. The side effects and clinical outcome for patients treated with intraportal MMC were compared with those for a control group. The controls included an MMC (+) group that received intravenous MMC, and a MMC (-) group that did not. The intraportal MMC group showed less toxicity compared with the MMC (+) group and a prospective effect on survival and liver metatstasls. These results suggested that our schedule for repetitive intraportal MMC was adequate.","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.34429/00003134","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山梨医科大学医学会"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10044054","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0912-0025","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-27"}],"displaytype":"detail","filename":"AN10044054_07_03_02.pdf","filesize":[{"value":"625.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"AN10044054_07_03_02.pdf","url":"https://yamanashi.repo.nii.ac.jp/record/3141/files/AN10044054_07_03_02.pdf"},"version_id":"a997f163-1807-408a-a91c-9ed5a33a4e03"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Repetitive portal administration"},{"subitem_subject":"Mitomycin C"},{"subitem_subject":"Pharmacokinetic study"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<Original Article> Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<Original Article> Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -"}]},"item_type_id":"10001","owner":"1","path":["293"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-05-18"},"publish_date":"2010-05-18","publish_status":"0","recid":"3141","relation_version_is_last":true,"title":["<Original Article> Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-10-11T07:39:22.604496+00:00"}